RI
risankizumab (Skyrizi)
AbbVie, Inc. · IL23A · Monoclonal Antibodies
Status
✓ Approved
Indications
13 conditions
Clinical Trials
85 total
Active Trials
32 ongoing
Targets
IL23A
What is risankizumab?
Last updated: February 2025risankizumab is a monoclonal antibodies developed by AbbVie, Inc.. It is approved for therapeutic indications via injectable (others) or intravenous (iv) or subcutaneous injection.
Drug Profile
| Generic Name | risankizumab-rzaa |
| Brand Names | Skyrizi |
| Company | AbbVie, Inc. |
| Drug Class | Monoclonal Antibodies, Antibody |
| Molecular Target | IL23A |
| Route | Injectable (Others), Intravenous (IV), Subcutaneous Injection |
| Status | Approved |
Sources: ClinicalTrials.gov, AbbVie, Inc.
Mechanism of Action
Molecular Targets
risankizumab acts on 1 molecular target:
| IL23A | interleukin 23 subunit alpha (P19, SGRF) |
Want deeper analysis?Noah AI can explain complex mechanisms and compare to similar drugs.
Clinical Trials
There are currently 85 clinical trials registered, with 32 actively ongoing.
| Trial ID | Phase | Title | Status |
|---|---|---|---|
| NCT07071519 | Phase 3 | A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab | ● Recruiting |
| NCT06548542 | Phase 2 | A Phase 2a Multicenter, Randomized, Platform Study of Targeted Therapies for the Treatment of Adult | ● Recruiting |
| NCT06880744 | Phase 3 | Phase 3b, Multicenter, Randomized, Open-Label Study of Risankizumab Compared to Vedolizumab for the | ● Recruiting |
| NCT05995353 | Phase 3 | A Phase 3, Multi-Center Study to Evaluate the Pharmacokinetics, Efficacy, and Safety of Risankizumab | ● Recruiting |
| NCT06333860 | Phase 4 | A Phase 4 Multicenter, Randomized, Open-label, Efficacy Assessor Blinded Study of Risankizumab Compa | ● Active Not Recruiting |
| NCT06624228 | Phase 3 | A Multicenter, Randomized, Double-Blind, Risankizumab-Controlled, Parallel-Group Study to Evaluate t | ● Active Not Recruiting |
+81 more trials available with free account
Sign up free to view all clinical trials →Analyze Full Trial DataNoah can compare efficacy across trials and generate reports.
Therapeutic Indications
risankizumab is developed for 13 unique indications across 4 therapeutic areas.
| Therapeutic Area | Condition | Phase |
|---|---|---|
| Gastrointestinal disorders | Colitis ulcerative | ✓ Approved |
| Gastrointestinal disorders | Crohn's disease | ✓ Approved |
| Skin and subcutaneous tissue disorders | Dermatitis allergic | ✓ Approved |
| Skin and subcutaneous tissue disorders | Dermatitis atopic | ✓ Approved |
| Skin and subcutaneous tissue disorders | Psoriasis | ✓ Approved |
+8 more indications available with free account
Sign up free to view all indications →